Edgewise Therapeutics Files 8-K on Officer/Director Changes
Ticker: EWTX · Form: 8-K · Filed: Nov 20, 2025 · CIK: 1710072
| Field | Detail |
|---|---|
| Company | Edgewise Therapeutics, Inc. (EWTX) |
| Form Type | 8-K |
| Filed Date | Nov 20, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $10 billion, $40,000, $700,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-changes, director-changes, filing
Related Tickers: EDSA
TL;DR
Edgewise Therapeutics (EDSA) filed an 8-K, watch for leadership changes.
AI Summary
Edgewise Therapeutics, Inc. filed an 8-K on November 20, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in leadership or governance at Edgewise Therapeutics, which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors or officers can signal internal shifts that may affect company strategy or stability.
Key Players & Entities
- Edgewise Therapeutics, Inc. (company) — Registrant
- November 19, 2025 (date) — Earliest event reported
- November 20, 2025 (date) — Date of report
- 001-40236 (company) — SEC File Number
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates events related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', but the specific details of these changes are not provided in the provided text.
When was the earliest event reported in this 8-K?
The earliest event reported in this 8-K was on November 19, 2025.
What is the company's principal executive office address?
The principal executive offices are located at 1715 38th St., Boulder, CO 80301.
What is the company's telephone number?
The company's telephone number is (720) 262-7002.
What other items are included in this 8-K filing?
In addition to the personnel changes, the filing also includes 'Financial Statements and Exhibits'.
Filing Stats: 893 words · 4 min read · ~3 pages · Grade level 10.8 · Accepted 2025-11-20 17:07:45
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share EWTX The Nasdaq
- $10 billion — quired by Merck & Co. for approximately $10 billion in October 2025. As Chief Commercial Of
- $40,000 — his includes an annual cash retainer of $40,000 per year for service as an outside dire
- $700,000 — nting principles equal to approximately $700,000. This stock option vests as to 1/36th o
Filing Documents
- tm2531112d1_8k.htm (8-K) — 30KB
- tm2531112d1_ex99-1.htm (EX-99.1) — 12KB
- tm2531112d1_ex99-1img001.jpg (GRAPHIC) — 31KB
- 0001104659-25-114660.txt ( ) — 250KB
- ewtx-20251119.xsd (EX-101.SCH) — 3KB
- ewtx-20251119_lab.xml (EX-101.LAB) — 33KB
- ewtx-20251119_pre.xml (EX-101.PRE) — 22KB
- tm2531112d1_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Election of Director On November 19, 2025, the Board of Directors (the "Board") of Edgewise Therapeutics, Inc. (the "Company") appointed Christopher Martin to serve as a Class I director, with a term expiring at the Company's 2028 annual meeting of stockholders. Mr. Martin, age 49, served as Chief Commercial Officer from January 2024 to October 2025 for Verona Pharma, which was acquired by Merck & Co. for approximately $10 billion in October 2025. As Chief Commercial Officer, Mr. Martin was responsible for building the commercial organization and launch strategy for the company's first product launch, Ohtuvayre (ensifentrine). Mr. Martin previously served in other management positions at Verona, including Senior Vice President of Commercial from January 2022 to December 2023 and Vice President of Commercial from June 2020 and December 2022. Prior, he served as Executive Director of Marketing at SK Life Science which is focused on developing novel therapeutics for central nervous system conditions from March 2018 to June 2020. Mr. Martin was instrumental in developing the commercial and marketing strategy and the framework for launching their first commercial product, XCOPRI (cenobamate tablets). Until its acquisition by Melinta Therapeutics, Mr. Martin was Head of Marketing at Cempra where he led the development and launch strategy for the company's first product, solithromycin. Prior to Cempra, he was at Salix Pharmaceuticals for 10 years in roles of increasing responsibility and led the Xifaxan marketing team during the company's acquisition by Valeant Pharmaceuticals. Mr. Martin received a Bachelor of Science in Financial Management from Clemson University. The Board determined that Mr. Martin qualifies as independent under the director independence standards set forth in the rules and regulations of
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 20, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL documents)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDGEWISE THERAPEUTICS, INC. By: /s/ John Moore John Moore General Counsel Date: November 20, 2025